Precigen (NASDAQ:PGEN) Hits New 52-Week High – Still a Buy?

Posted by George Bondi on Sep 30th, 2026

Precigen, Inc. (NASDAQ:PGEN – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $8.31 and last traded at $8.3840, with a volume of 1055457 shares trading hands. The stock had previously closed at $8.05.

Wall Street Analysts Forecast Growth

PGEN has been the topic of several recent research reports. B. Riley Financial started coverage on Precigen in a research report on Friday, September 25th. They set a “buy” rating and a $12.00 price objective on the stock. Zacks Research raised Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Finally, HC Wainwright upped their price objective on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.67.

Check Out Our Latest Report on Precigen

Precigen Trading Up 6.1%

The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The firm has a 50-day moving average of $6.88 and a 200-day moving average of $5.24. The firm has a market capitalization of $3.05 billion, a P/E ratio of -8.22 and a beta of 1.02.

Precigen (NASDAQ:PGEN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The business had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. The company’s revenue was up 6322.7% compared to the same quarter last year. On average, equities research analysts anticipate that Precigen, Inc. will post 0.24 EPS for the current fiscal year.

Insider Buying and Selling at Precigen

In related news, Director Jeffrey Kindler sold 185,000 shares of Precigen stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the transaction, the director directly owned 17,100 shares of the company’s stock, valued at approximately $127,224. The trade was a 91.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Rutul Shah sold 15,342 shares of Precigen stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total transaction of $115,065.00. Following the sale, the chief operating officer directly owned 468,865 shares of the company’s stock, valued at $3,516,487.50. This represents a 3.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 401,511 shares of company stock worth $2,801,508 over the last ninety days. Company insiders own 41.40% of the company’s stock.

Institutional Investors Weigh In On Precigen

Large investors have recently modified their holdings of the business. State of Wyoming purchased a new position in Precigen in the 1st quarter worth $27,000. Royal Bank of Canada lifted its position in Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new position in Precigen during the 1st quarter worth about $43,000. Y Intercept Hong Kong Ltd purchased a new position in Precigen in the 1st quarter valued at approximately $49,000. Finally, Nations Financial Group Inc. IA ADV acquired a new position in shares of Precigen in the first quarter worth $60,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

(Get Free Report)

Precigen, Inc (NASDAQ:PGEN) is a biotechnology company focused on developing gene and cell therapies for cancer and other serious diseases. The company uses its synthetic biology platforms to engineer targeted medicines designed to improve treatment effectiveness, durability and safety.

Precigen’s technology portfolio includes its UltraCAR-T platform for developing next-generation CAR-T cell therapies, the AdenoVerse platform for gene delivery and immunotherapy applications, and ActoBiotics technology for the localized delivery of therapeutic proteins.